Peter Paul De Deyn
Arzt,
Neurowissenschaftler
Hat mitgewirkt an:
-
Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial
-
A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer’s disease
-
No added diagnostic value of non-phosphorylated tau fraction (p-taurel) in CSF as a biomarker for differential dementia diagnosis
-
Let Us Talk Money: Subjectively Reported Financial Performance of People Living with Neurodegenerative Diseases—A Systematic Review